No profile data available.
Rigel Pharmaceuticals, Inc. (RIGL) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in South San Francisco, United States, with about 172 full-time employees.
It reported revenue of $294.28 million for fiscal year 2025, up 64.1% from fiscal year 2024, and net income of $367.02 million. Its market capitalization was $908.08 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
Rigel Pharmaceuticals reported $294.28 million in revenue for fiscal year 2025, up 64.1% from $179.28 million in fiscal year 2024.
$908.08 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Alvotech (ALVO), Zenas BioPharma, Inc. (ZBIO), Alumis Inc. (ALMS), Monte Rosa Therapeutics, Inc. (GLUE).